rss
J Med Genet 2009;46:641-644 doi:10.1136/jmg.2009.066969
  • Letter to JMG

Differences in SMN1 allele frequencies among ethnic groups within North America

This article has been UnlockedFree via Creative Commons: OPEN ACCESS
  1. B C Hendrickson1,
  2. C Donohoe1,
  3. V R Akmaev1,
  4. E A Sugarman1,
  5. P Labrousse1,
  6. L Boguslavskiy1,
  7. K Flynn1,
  8. E M Rohlfs1,
  9. A Walker1,
  10. B Allitto1,
  11. C Sears2,3,
  12. T Scholl1
  1. 1
    Genzyme Genetics, Westborough, Massachusetts, USA
  2. 2
    Department of Hematology and Oncology, Children’s Hospital, Boston, Massachusetts, USA
  3. 3
    Broad Institute, Cancer Program, Cambridge, Massachusetts, USA
  1. Correspondence to Dr T Scholl, Genzyme Genetics, 3400 Computer Drive, Westborough, MA 01581, USA; Thomas.Scholl{at}Genzyme.com
  • Received 6 February 2009
  • Revised 30 April 2009
  • Accepted 12 May 2009
  • Published Online First 21 July 2009

Abstract

Background: Spinal muscular atrophy (SMA) is the most common inherited lethal disease of children. Various genetic deletions involving the bi-allelic loss of SMN1 exon 7 are reported to account for 94% of affected individuals. Published literature places the carrier frequency for SMN1 mutations between 1 in 25 and 1 in 50 in the general population. Although SMA is considered to be a pan-ethnic disease, carrier frequencies for many ethnicities, including most ethnic groups in North America, are unknown.

Objectives and methods: To provide an accurate assessment of SMN1 mutation carrier frequencies in African American, Ashkenazi Jewish, Asian, Caucasian, and Hispanic populations, more than 1000 specimens in each ethnic group were tested using a clinically validated, quantitative real-time polymerase chain reaction (PCR) assay that measures exon 7 copy number.

Results: The observed one-copy genotype frequency was 1 in 37 (2.7%) in Caucasian, 1 in 46 (2.2%) in Ashkenazi Jew, 1 in 56 (1.8%) in Asian, 1 in 91 (1.1%) in African American, and 1 in 125 (0.8%) in Hispanic specimens. Additionally, an unusually high frequency of alleles with multiple copies of SMN1 was identified in the African American group (27% compared to 3.3–8.1%). This latter finding has clinical implications for providing accurate adjusted genetic risk assessments to the African American population.

Conclusions: Differences in the frequency of SMA carriers were significant among several ethnic groups. This study provides an accurate assessment of allele frequencies and estimates of adjusted genetic risk that were previously unavailable to clinicians and patients considering testing.

Footnotes

  • Competing interests All authors, except C S, declare the potential for duality of interest because they are employed by, and receive salaries from, Genzyme Genetics, the institution that funded this research. Genzyme is engaged in clinical testing of SMN1 for SMA carrier screening.

  • Patient consent Not required.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

This article has been Unlocked
Free via Creative Commons: OPEN ACCESS

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JMG.
View free sample issue >>

Free archive
The full back archive is now available for JMG. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

  • Latest genetics jobs

    Latest genetics jobs